Dicerna doubles its footprint; Sanofi weighs a sell-off;

@FierceBiotech: ICYMI yesterday: Three more biotechs target $175M in IPO cash amid market tumult. Report | Follow @FierceBiotech

@DamianFierce: A+ photo choice. It's like he's snatching the savings right outta your hand. More from the WSJ | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday, check out the latest issue of FierceBiotech ResearchReport | Follow @EmilyMFierce

> After a booming year on Wall Street, Dicerna Pharmaceuticals ($DRNA) is doubling its capacity and moving into a new headquarters in Cambridge, MA. Story

> Sanofi ($SNY) is considering selling off its older drugs for more than $8 billion, according to reports. More

> Microbiomics developer Seres Health has wrapped up enrollment in an open-label study of its treatment for Clostridium difficile. News

Medical Device News

@FierceMedDev: Boston Scientific wins expanded European approval for Lotus transcatheter valve system. Article | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Placenta plays vital role in fetal development, but much remains in the way of medical breakthroughs and research. More from the NYT | Follow @EmilyWFierce

> St. Jude Medical charts positive Q2 numbers, thanks in part to recent M&A. Article

> Medtronic's Hospital of the Future akin to birthing an elephant. Story

Pharma News

@FiercePharma: Top-read on FP Tuesday: J&J's powerhouse drug launches drive 21% boost to Q2 pharma sales. Story | Follow @FiercePharma

@EricPFierce: GSK investing $25M in Codexis technology as it looks for 'more elegant' ways to manufacture APIs. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Merck is aiming to revive Zilmax sales, but it's not that easy after safety scare. Article | Follow @CarlyHFierce

> Pfizer amps up its 'Get old' campaign with more content, more social media. Item

> Reuters: Sanofi in $8.5B sell-off talks with Mylan, Abbott, private equity. Report

> Sanofi and others hit hard by India's price caps on heart and diabetes drugs. More

> Ex-China staffers sue GSK for 'illegal' termination amid bribery scandal. Report

Drug Delivery News

> Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve. Item

> UPenn researchers develop nanogel for mitigating lung inflammation. Report

> Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer. More

> Delivering breast cancer drug through the skin grants disease prevention. Article

> Nasal version of naloxone for opioid overdose gets on FDA's fast track. Story

Diagnostics News

> Asuragen gains New York state's OK to launch autism and thyroid tests. More

> Roche and Merck KGaA team on a multicancer companion diagnostic test. Story

> MGC Diagnostics grows international reach with Belgian M&A deal. News

> NeuroVision Imaging's CEO discloses approval timeline for eye test to help spot Alzheimer's. Report

> Maryland researchers expand usefulness of schizophrenia biomarker found in saliva. Article

Pharma Marketing News

> J&J's new hep C med Olysio aced Q2. So why are investors worried? More

> Orphan drug approvals are up, but prices are up more. Report

> Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Story

> In social media, what's easier to grasp--an FDA webinar or an FDA warning letter? More

> Roche's Avastin steps on FDA fast track for new cervical cancer use. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.